Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Quick Guide’ To Help EU Clinical Trial Sponsors As CTIS Hits 31 January Milestone

Executive Summary

Just a day before it became mandatory to use the single-portal Clinical Trial Information System, the European Commission published concise advice for sponsors and investigators who want to conduct trials in Europe.

You may also be interested in...



EU Clinical Trials System Should Be Free Of Major Bugs Within Three Months

A senior executive at the European Medicines Agency says that all major technical problems with the EU Clinical Trials Information System are close to being resolved, and will free up time to focus on delivering much needed improvements and new functionalities.

EudraCT Vs CTIS: How EU Trial Submissions Fared In Run Up To Mandatory Requirements

The European Medicines Agency has published the latest data on the EU clinical trials environment showing how sponsors chose to submit trial applications just ahead of the crucial 31 January 2023 deadline, when the use of the new clinical trials portal became mandatory.

Sponsors Under Fire For Excessive Data Redactions & Deferrals In EU Clinical Trials Portal

An analysis of publicly available information in the EU Clinical Trials Information System shows how commercial and academic sponsors differ in their approach to transparency. There are also concerns around the lack of “push back” from EU member states to address potential non-compliance. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel